Press Release & Community Statement: Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
Industry News
News|May 29 2026
Community Letter: Update from PTC Therapeutics
Industry News
News|May 15 2026
Press release and community statement: Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights
Industry News
News|Aug 19 2025
Press Release & Community Statement: PTC Therapeutics Receives Complete Response Letter for Vatiquinone NDA
Industry News
News|Aug 7 2025
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results
Industry News
News|Mar 24 2025
Press Release & Community Update: Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Industry News
News|Mar 24 2025
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Industry News
News|Feb 19 2025
Press Release & Community Statement: PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich’s Ataxia
Industry News
News|Feb 4 2025
Letter to the FA Community from Astellas Pharma
Industry News
News|Jan 29 2025
Webinar Recording: PTC Therapeutics Vatiquinone Program January 2025 Update
FARA News | Industry News
News|Jan 23 2025
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia
Industry News
News|Jan 21 2025
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia